Q32 Bio Inc QTTB 深 沪
等待开盘 08-10 09:30:00 美东时间
15.60
-0.600
-3.70%
华盛通- 最 高16.9587
- 今 开16.58
- 成交量 50.40万股
- 最 低 15.02
- 昨 收 16.20
- 总市值 0
- 52周最高 23.5699
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.6215
- 委 比 -50.00%
- 总股本 --
- 历史最高 53.725
- 量 比 0.87
- 振 幅 11.97%
- 历史最低 0.43
- 每 手 1
- 风险率 4.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech drops 5%. Commodities mixed. European and Asian markets close mixed.
07-14 00:48
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why
Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.
07-13 20:55
Market-Moving News for July 13th
QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. AGEN: 36% | Agenus To Raise $85M To
07-13 19:14
Q32 Bio Files Prospectus To Launch New $75M At-The-Market Offering Program
As previously disclosed, on March 27, 2026, Q32 Bio Inc. (the "Company") entered into a Controlled Equity OfferingSM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. (the "Sales Agent"),
04-25 04:12
Q32 Bio Mark Iwicki Withdraws Resignation From Q32 Bio Board; Mark Iwicki To Remain Chair Of Board
-SEC Filing
2025-12-20 05:57
Crude Oil Gains Over 1%; ISM Manufacturing PMI Falls In November
U.S. stocks traded lower midway through trading, with the Dow Jones falling aro...
2025-12-02 01:31
Dow Dips 200 Points; Q32 Bio Shares Jump
U.S. stocks traded lower this morning, with the Dow Jones falling around 200 po...
2025-12-01 22:58
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.
2025-12-01 22:43
Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
2025-12-01 20:37
